Targeting Molecular Residual Disease Using Novel Technologies and Clinical Trials Design in Head and Neck Squamous Cell Cancer
Open Access
- 28 March 2023
- book chapter
- Published by Springer Nature
- p. 305-314
Abstract
High-risk human papillomavirus (HPV)-related and most cases of HPV-negative locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC) have substantial risks of relapse despite definitive therapy, and thus represent conditions of unmet clinical need. The ability now exists to detect molecular residual disease (MRD) in these patients post-definitive treatment such as surgery or (chemo)radiotherapy using novel and highly sensitive and specific technologies to measure cancer-derived circulating biomarkers. The positive and negative predictive values of these assays to forecast cancer recurrence, as well as the lead time of circulating tumor DNA (ctDNA) detection before clinical relapse, are relevant as these parameters rationalize the design of clinical trials for cancer interception in the MRD setting. Currently, there is evidence that interception in the MRD setting yields benefit in clinical outcome in some cancers, but such data do not yet exist in LA-HNSCC and will require prospective testing via clinical trials.Keywords
This publication has 27 references indexed in Scilit:
- Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal CancerJournal of Clinical Oncology, 2020
- Circulating tumor DNA and liquid biopsy in oncologyNature Cancer, 2020
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyThe Lancet, 2019
- Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal CancerClinical Cancer Research, 2019
- Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal CancerJAMA Oncology, 2019
- Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic RecurrenceClinical Cancer Research, 2019
- Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder CarcinomaJournal of Clinical Oncology, 2019
- Sensitive tumour detection and classification using plasma cell-free DNA methylomesNature, 2018
- Sequencing-based counting and size profiling of plasma Epstein–Barr virus DNA enhance population screening of nasopharyngeal carcinomaProceedings of the National Academy of Sciences, 2018
- Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort studyThe Lancet Oncology, 2016